Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 25, 2020 - Issue 3
Submit an article Journal homepage
1,574
Views
48
CrossRef citations to date
0
Altmetric
Review

Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs

Madia Lozuponea Neurodegenerative Disease Unit, Department of Basic Medicine, Neuroscience, and Sense Organs, University of Bari Aldo Moro, Bari, ItalyCorrespondence[email protected]
View further author information
,
Vincenzo Solfrizzib “Cesare Frugoni” Internal and Geriatric Medicine and Memory Unit, University of Bari “Aldo Moro”, Bari, ItalyView further author information
,
Francesca D’Ursoc Psychiatric Unit, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, ItalyView further author information
,
Ilaria Di Gioiac Psychiatric Unit, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, ItalyView further author information
,
Rodolfo Sardoned Population Health Unit - “Salus in Apulia Study” - National Institute of Gastroenterology, “Saverio De Bellis”, Research Hospital, Bari, ItalyView further author information
,
Vittorio Dibellod Population Health Unit - “Salus in Apulia Study” - National Institute of Gastroenterology, “Saverio De Bellis”, Research Hospital, Bari, Italy;e Department of Orofacial Pain and Dysfunction, Academic Centre of Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, The NetherlandsView further author information
,
Roberta Stalloned Population Health Unit - “Salus in Apulia Study” - National Institute of Gastroenterology, “Saverio De Bellis”, Research Hospital, Bari, ItalyView further author information
,
Angelo Liguorid Population Health Unit - “Salus in Apulia Study” - National Institute of Gastroenterology, “Saverio De Bellis”, Research Hospital, Bari, ItalyView further author information
,
Chiara Ciritellaf Physical and Rehabilitation Medicine Department, University of Foggia, Foggia, ItalyView further author information
,
Antonio Danieleg Institute of Neurology, Catholic University of Sacred Heart, Rome, Italy;h Institute of Neurology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ItalyView further author information
,
Antonello Bellomoc Psychiatric Unit, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, ItalyView further author information
,
Davide Seripai Geriatric Unit and Gerontology-Geriatrics Research Laboratory, Department of Medical Sciences, IRCCS Casa Sollievo Della Sofferenza, Foggia, Italy;j Hematology and Stem Cell Transplant Unit, Vito Fazzi Hospital, ASL Lecce, Lecce, ItalyView further author information
&
Francesco Panzad Population Health Unit - “Salus in Apulia Study” - National Institute of Gastroenterology, “Saverio De Bellis”, Research Hospital, Bari, ItalyCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0002-7220-0656View further author information
ORCID Icon show all
Pages 319-335 | Received 06 May 2020, Accepted 07 Aug 2020, Published online: 20 Aug 2020

Citations (48)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Madia Lozupone, Giuseppe Berardino, Anita Mollica, Rodolfo Sardone, Vittorio Dibello, Roberta Zupo, Luisa Lampignano, Fabio Castellana, Ilaria Bortone, Roberta Stallone, Antonio Daniele, Mario Altamura, Antonello Bellomo, Vincenzo Solfrizzi & Francesco Panza. (2022) ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer’s disease. Expert Opinion on Investigational Drugs 31:8, pages 759-771.
Read now
Sheila A Doggrell. (2021) Still grasping at straws: donanemab in Alzheimer’s disease. Expert Opinion on Investigational Drugs 30:8, pages 797-801.
Read now

Articles from other publishers (46)

Joo-Hee Lee, Nivethasri Lakshmana Perumal, Sehee Kwon, Hee-Cheol Kim, Na-Hyun Ahn, Su-Bin Choi, Eunjin Hwang, Hyoryeong Song, David R. Elmaleh, Aryun Kim, Woong-Suk Yang, Cheorl-Ho Kim, Byeong-Churl Jang, Sungwoon Choi & Seung-Hoon Yang. (2023) The Derivatives of Cromolyn Ameliorate the Abnormal Misfolding of Amyloid Proteins and Neuroinflammation in the Neural Cells. Current Medicinal Chemistry 30:39, pages 4479-4491.
Crossref
Zhimin Wu, Tao Zhang, Xiaofei Ma, Shuai Guo, Qingqing Zhou, Arshad Zahoor & Ganzhen Deng. (2023) Recent advances in anti-inflammatory active components and action mechanisms of natural medicines. Inflammopharmacology 31:6, pages 2901-2937.
Crossref
Zhao-Di Xia, Ruo-Xin Ma, Jin-Feng Wen, Yu-Fei Zhai, Yu-Qi Wang, Feng-Yun Wang, Dan Liu, Xiao-Long Zhao, Bao Sun, Pu Jia & Xiao-Hui Zheng. (2023) Pathogenesis, Animal Models, and Drug Discovery of Alzheimer’s Disease. Journal of Alzheimer's Disease 94:4, pages 1265-1301.
Crossref
Yauhen Statsenko, Tetiana Habuza, Darya Smetanina, Gillian Lylian Simiyu, Sarah Meribout, Fransina Christina King, Juri G. Gelovani, Karuna M. Das, Klaus N.-V. Gorkom, Kornelia Zaręba, Taleb M. Almansoori, Miklós Szólics, Fatima Ismail & Milos Ljubisavljevic. (2023) Unraveling Lifelong Brain Morphometric Dynamics: A Protocol for Systematic Review and Meta-Analysis in Healthy Neurodevelopment and Ageing. Biomedicines 11:7, pages 1999.
Crossref
Weimin Qiu, Hui Liu, Yijun Liu, Xin Lu, Lei Wang, Yanyu Hu, Feng Feng, Qi Li & Haopeng Sun. (2023) Regulation of beta‐amyloid for the treatment of Alzheimer's disease: Research progress of therapeutic strategies and bioactive compounds. Medicinal Research Reviews 43:4, pages 1091-1140.
Crossref
Daniel A. Lichlyter, Zachary A. Krumm, Todd A. Golde & Sylvain Doré. (2022) Role of CRF and the hypothalamic‐pituitary‐adrenal axis in stroke: revisiting temporal considerations and targeting a new generation of therapeutics. The FEBS Journal 290:8, pages 1986-2010.
Crossref
Rong Wei, Jun-Qiu He, Wen-Hua Chen & Kin Yip Tam. (2023) Evaluations of the neuroprotective effects of a dual-target isoquinoline inhibitor in the triple transgenic mouse model of Alzheimer's disease. Neuroscience Letters 802, pages 137166.
Crossref
Yanqing Zhu. (2023) The Current Status of Drugs Related to Amyloid β-protein in Alzheimer's Disease. Highlights in Science, Engineering and Technology 36, pages 762-767.
Crossref
Mohammad Mahdi Ghazimoradi, Mozhgan Ghobadi Pour, Ehsan Ghoushi, Hadise Karimi Ahmadabadi & Mahmoud Rafieian-Kopaei. (2023) A Review on Garlic as a Supplement for Alzheimer’s Disease: A Mechanistic Insight into its Direct and Indirect Effects. Current Pharmaceutical Design 29:7, pages 519-526.
Crossref
Isabela F. L. Mota, Larissa S. de Lima, Bruna de M. Santana, Giovanna de A. M. Gobbo, João V. M. L. Bicca, Juliana R. M. Azevedo, Letícia G. Veras, Rodrigo de A. A. Taveira, Gabriela B. Pinheiro & Márcia R. Mortari. (2021) Alzheimer’s Disease: Innovative Therapeutic Approaches Based on Peptides and Nanoparticles. The Neuroscientist 29:1, pages 78-96.
Crossref
Prashanth Punyakoti, Tapan Behl, Aayush Sehgal, Shivam Yadav, Monika Sachdeva, Md. Khalid Anwer, Celia Vargas-De-La-Cruz, Thangavel Venkatachalam, Maaz Naqvi, Raman Verma & Hardeep Singh Tuli. (2023) Postulating the possible cellular signalling mechanisms of antibody drug conjugates in Alzheimer's disease. Cellular Signalling 102, pages 110539.
Crossref
Nicole Shu Ling Yeo-Teh & Bor Luen Tang. (2023) A Review of Scientific Ethics Issues Associated with the Recently Approved Drugs for Alzheimer’s Disease. Science and Engineering Ethics 29:1.
Crossref
Houman Sotoudeh, Mohammadreza Alizadeh, Ramin Shahidi, Parnian Shobeiri, Natelson love & Aparna Singhal. (2023) Subcortical signal alteration of corticospinal tracts. A radiologic manifestation of ARIA: A case report. Radiology Case Reports 18:1, pages 275-279.
Crossref
Christian BehlChristian Behl. 2023. Alzheimer’s Disease Research. Alzheimer’s Disease Research 309 350 .
Arjuna Abitbol, Brody Mallard, Evelin Tiralongo & Joe Tiralongo. (2022) Mushroom Natural Products in Neurodegenerative Disease Drug Discovery. Cells 11:23, pages 3938.
Crossref
Asra Nasir Khan & Rizwan Hasan Khan. (2022) Protein misfolding and related human diseases: A comprehensive review of toxicity, proteins involved, and current therapeutic strategies. International Journal of Biological Macromolecules 223, pages 143-160.
Crossref
Chuli Song, Tianyu Zhang & Yingjiu Zhang. (2022) Conformational Essentials Responsible for Neurotoxicity of Aβ42 Aggregates Revealed by Antibodies against Oligomeric Aβ42. Molecules 27:19, pages 6751.
Crossref
Yu-Mei Jia, Cai-Feng Zhu, Ze-Yu She, Meng-Meng Wu, Yang-Yang Wu, Bing-Yuan Zhou & Na Zhang. (2022) Effects on Autophagy of Moxibustion at Governor Vessel Acupoints in APP/PS1double-Transgenic Alzheimer’s Disease Mice through the lncRNA Six3os1/miR-511-3p/AKT3 Molecular Axis. Evidence-Based Complementary and Alternative Medicine 2022, pages 1-10.
Crossref
Shubhima Grover & Seema Jain. (2022) Aducanumab: a review of the first approved amyloid-targeting antibody for Alzheimer’s disease. Drugs & Therapy Perspectives 38:10, pages 443-454.
Crossref
Livia La Barbera, Emanuele Mauri, Marcello D’Amelio & Manuele Gori. (2022) Functionalization strategies of polymeric nanoparticles for drug delivery in Alzheimer’s disease: Current trends and future perspectives. Frontiers in Neuroscience 16.
Crossref
Shaomin Li & Andrew M. Stern. (2022) Bioactive human Alzheimer brain soluble Aβ: pathophysiology and therapeutic opportunities. Molecular Psychiatry 27:8, pages 3182-3191.
Crossref
Jerry R. Colca & Brian N. Finck. (2022) Metabolic Mechanisms Connecting Alzheimer’s and Parkinson’s Diseases: Potential Avenues for Novel Therapeutic Approaches. Frontiers in Molecular Biosciences 9.
Crossref
Fredrik Blomgren, Alexander Rodin, Wojciech Chrobak, Dawid Wojciech Pacut, Jan Swenson & Inna Ermilova. (2022) Two statins and cromolyn as possible drugs against the cytotoxicity of Aβ(31–35) and Aβ(25–35) peptides: a comparative study by advanced computer simulation methods. RSC Advances 12:21, pages 13352-13366.
Crossref
Miren Altuna, Gonzalo Olmedo-Saura, María Carmona-Iragui & Juan Fortea. (2022) Mechanisms Involved in Epileptogenesis in Alzheimer’s Disease and Their Therapeutic Implications. International Journal of Molecular Sciences 23:8, pages 4307.
Crossref
Lauren Owens, Joshua Bracewell, Alexandre Benedetto, Neil Dawson, Christopher Gaffney & Edward Parkin. (2022) BACE1 Overexpression Reduces SH-SY5Y Cell Viability Through a Mechanism Distinct from Amyloid-β Peptide Accumulation: Beta Prime-Mediated Competitive Depletion of sAβPPα. Journal of Alzheimer's Disease 86:3, pages 1201-1220.
Crossref
Tapan Behl, Ishnoor Kaur, Aayush Sehgal, Sukhbir Singh, Neelam Sharma, Hafiz A. Makeen, Mohammed Albratty, Hassan A. Alhazmi, Shatha Ghazi Felemban, Amal M. Alsubayiel, Saurabh Bhatia & Simona Bungau. (2022) “Aducanumab” making a comeback in Alzheimer’s disease: An old wine in a new bottle. Biomedicine & Pharmacotherapy 148, pages 112746.
Crossref
Hari Madhav, Ehtesham Jameel, Mohammad Rehan & Nasimul Hoda. (2022) Recent advancements in chromone as a privileged scaffold towards the development of small molecules for neurodegenerative therapeutics. RSC Medicinal Chemistry 13:3, pages 258-279.
Crossref
Jae-Won Jang. (2022) New therapeutic opportunities for Alzheimer disease. Journal of Geriatric Neurology 1:1, pages 15-21.
Crossref
Jiachen Wen, Dan Liu & Linxiang Zhao. (2022) Small molecules targeting γ-secretase and their potential biological applications. European Journal of Medicinal Chemistry 232, pages 114169.
Crossref
Fangcheng Fan, Hua Liu, Xiaojie Shi, Yangwen Ai, Qingshan Liu & Yong Cheng. (2022) The Efficacy and Safety of Alzheimer’s Disease Therapies: An Updated Umbrella Review. Journal of Alzheimer's Disease 85:3, pages 1195-1204.
Crossref
Azusa Sugimoto & Kenjiro Ono. 2022. Autophagy Dysfunction in Alzheimer's Disease and Dementia. Autophagy Dysfunction in Alzheimer's Disease and Dementia 73 89 .
Navjot Kaur, Vanktesh Kumar, Thatikayala Mahender, Indrani Maji, Srushti Mahajan, Mayur Aalhate, Pankaj Kumar Singh & Sanjeev Kumar Sahu. 2022. Nanomedical Drug Delivery for Neurodegenerative Diseases. Nanomedical Drug Delivery for Neurodegenerative Diseases 67 79 .
Chenyu Xia & Qiang Ma. (2021) The Levels of Amyloid β-Protein and P181 in Peripheral Blood of Patients with Alzheimer’s Disease Combined with Helicobacter pylori Infection and Their Clinical Significance. Computational and Mathematical Methods in Medicine 2021, pages 1-6.
Crossref
Nicholas E. Johnson & Ericka Greene. (2021) Neurologic Therapeutics in 2035. Neurology 97:24, pages 1121-1127.
Crossref
Bin Hu, Chi Geng, Feng Guo, Ying Liu, Yu-Chen Zong & Xiao-Yu Hou. (2021) GABAA receptor agonist muscimol rescues inhibitory microcircuit defects in the olfactory bulb and improves olfactory function in APP/PS1 transgenic mice. Neurobiology of Aging 108, pages 47-57.
Crossref
Anna Atlante, Daniela Valenti, Valentina Latina & Giuseppina Amadoro. (2021) Role of Oxygen Radicals in Alzheimer’s Disease: Focus on Tau Protein. Oxygen 1:2, pages 96-120.
Crossref
Qiang Zhang, Canhua Hao, Yuhang Miao, Yinling Yun, Xiaoya Sun, Yinbo Pan, Jie Sun & Xiaojing Wang. (2021) Design and synthesis of benzyl aminocoumarin and its anti-Alzheimer's activity. New Journal of Chemistry 45:37, pages 17287-17300.
Crossref
Shinghung Mak, Wenming Li, Hongjun Fu, Jialie Luo, Wei Cui, Shengquan Hu, Yuanping Pang, Paul R. Carlier, Karl Wahkeung Tsim, Rongbiao Pi & Yifan Han. (2021) Promising tacrine/huperzine A‐based dimeric acetylcholinesterase inhibitors for neurodegenerative disorders: From relieving symptoms to modifying diseases through multitarget. Journal of Neurochemistry 158:6, pages 1381-1393.
Crossref
Ae Young Lee. (2021) Amyloid-Targeting Drugs for the Treatment of Alzheimer Disease. Journal of the Korean Neurological Association 39:3, pages 134-140.
Crossref
Mario Tombini, Giovanni Assenza, Lorenzo Ricci, Jacopo Lanzone, Marilisa Boscarino, Carlo Vico, Alessandro Magliozzi & Vincenzo Di Lazzaro. (2021) Temporal Lobe Epilepsy and Alzheimer’s Disease: From Preclinical to Clinical Evidence of a Strong Association. Journal of Alzheimer's Disease Reports 5:1, pages 243-261.
Crossref
Morteza Abyadeh, Vivek Gupta, Veer Gupta, Nitin Chitranshi, Yunqi Wu, Ardeshir Amirkhani, Anna Meyfour, Samran Sheriff, Ting Shen, Kunal Dhiman, Ghasem H. Salekdeh, Paul A. Haynes, Stuart L. Graham & Mehdi Mirzaei. (2021) Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimer’s Disease. Aging and disease 12:8, pages 1964.
Crossref
Hari Shanker Sharma, Dafin F. Muresanu, Ala Nozari, José Vicente Lafuente, Anca D. Buzoianu, Seaab Sahib, Z. Ryan Tian, Igor Bryukhovetskiy, Igor Manzhulo, Preeti K. Menon, Ranjana Patnaik, Lars Wiklund & Aruna Sharma. 2021. Nanomedicine and Neuroprotection in Brain Diseases. Nanomedicine and Neuroprotection in Brain Diseases 1 97 .
Qian Zhang, Qingxiang Song, Xiao Gu, Mengna Zheng, Antian Wang, Gan Jiang, Meng Huang, Huan Chen, Yu Qiu, Bin Bo, Shanbao Tong, Rong Shao, Binyin Li, Gang Wang, Hao Wang, Yongbo Hu, Hongzhuan Chen & Xiaoling Gao. (2020) Multifunctional Nanostructure RAP‐RL Rescues Alzheimer's Cognitive Deficits through Remodeling the Neurovascular Unit. Advanced Science 8:2.
Crossref
Rosa Purgatorio, Nicola Gambacorta, Marco Catto, Modesto de Candia, Leonardo Pisani, Alba Espargaró, Raimon Sabaté, Saverio Cellamare, Orazio Nicolotti & Cosimo Altomare. (2020) Pharmacophore Modeling and 3D-QSAR Study of Indole and Isatin Derivatives as Antiamyloidogenic Agents Targeting Alzheimer’s Disease. Molecules 25:23, pages 5773.
Crossref
L. Gaussens, M. Baziard, A. de Mauléon, J. Delrieu, F. Nourhashémi, B. Vellas & M. Soto. (2020) Implémentation du programme ICOPE dans le parcours de soins du patient atteint d'une maladie d'Alzheimer ou maladie apparentée. NPG Neurologie - Psychiatrie - Gériatrie 20:120, pages 120S25-120S32.
Crossref
William M. Pardridge. (2020) Treatment of Alzheimer’s Disease and Blood–Brain Barrier Drug Delivery. Pharmaceuticals 13:11, pages 394.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.